By


BioAdvance Names Sam Katz as Chair and Elects J. Larry Jameson, M.D., Ph.D., and Lauren Lenfest as Directors
Read more here

By


QR Pharma Reports Results from SBIR Grant by NIA/NIH to Study Posiphen® and Metabolites in Various Models
Read more here

By


FDA Accepts Filing of New Drug Application (NDA) for Yaupon’s Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Read more here

By


Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
Read more here

By


Yaupon Therapeutics, Inc. Submits New Drug Application for Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Read more here

By


First-In-Class Novel Anti-Cancer Agent In Development By Niiki Pharma Shows Promising Phase I Results
Read more here